// App-Quantinova.ai

P262 : Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study

Researchers

Presenter

  • Atul Deodhar

Principal Investigators

  • Philip Helliwell

  • Wolf-Henning Boehncke

  • Elizabeth C Hsia

  • Alexa P Kollmeier

  • Ramanand A Subramanian

  • Xie L Xu

  • Shihong Sheng

  • Bei Zhou

  • Patricia C Gorecki

  • Christopher Ritchlin

Medical Centers

  • School of Nursing, Oregon Health & Science University, Portland, OR

  • School of Dentistry, University of Leeds, Leeds, UNITED KINGDOM

  • Departement de Medecine, Geneva University Hospitals, Geneva, SWITZERLAND

  • Janssen Research & Development, Janssen-Cilag Ltd, Spring House, PA, USA

  • Janssen Research & Development, Janssen-Cilag Ltd, Spring House, PA, USA

  • Janssen Research & Development, Janssen-Cilag Ltd, Spring House, PA, USA

  • Janssen Medical Affairs, Janssen-Cilag Ltd, High Wycombe, UNITED KINGDOM

  • Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY

Locations

  • United States

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Dactylitis

Biomarkers

  • N/A

Drug/Treatment

  • Interleukin

  • Apremilast

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved